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Abstract Carcinoembryonic antigen (CEA) is the best circu-
lating tumourmarker for colorectal livermetastasis (CLM) but
has suboptimal sensitivity and specificity. Circulating type IV
collagen (COLIV) is a new potential CLM marker. Here,
COLIV and CEA were measured in patients with resectable
CLM. COLIV levels were also related to the type of CLM.
The prognostic value of these markers and the type of CLMon
survival was evaluated. Preoperative plasma samples (n=94)
from patients (n=85) with CLM undergoing liver resection
were used. Seven patients underwent repeated liver resection.
Samples from 118 healthy individuals served as control.
Samples after liver resection (n=27) were analysed and relat-
ed to recurrence. COLIV and CEA levels were analysed, and
the type of CLM was classified using paraffinated tissue.
Results were analysed by logistic regression and receiver op-
erating characteristic (ROC) curve analysis. CLM patients had
significantly elevated levels of COLIV compared to controls
(p=0.001). The sensitivity of COLIV was not better than
CEA, but improved sensitivity for detecting CLM was ob-
served with a combination of the two markers compared to
using either marker alone (p=0.001). Circulating COLIV was
elevated in 81 % and CEA in 56 % of CLM patients at diag-
nosis, and high marker levels were related to poor survival. In
follow-up samples (n=27), patients with CLM recurrence (n=
14) had significantly elevated COLIV levels compared to pa-
tients without postoperative recurrence (n=10) (p=0.001).
COLIV is a promising tumour marker for CLM and can pos-
sibly be used to detect postoperative CLM recurrence. The
combination of COLIV and CEA is superior to either marker
alone in detecting CLM.
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Introduction
Circulating tumour markers can be used as tools for detecting
disease, defining prognosis and predicting the effect of treat-
ment and in the follow-up and surveillance of cancer patients.
For colorectal cancer (CRC) and colorectal liver metastases
(CLM), the most commonly used circulating biomarker is
carcinoembryonic antigen (CEA). This biomarker is mainly
used to detect recurrence of CRC and not for screening due to
low sensitivity and specificity [1, 2]. At CRC recurrence, 50–
60% of patients have increased levels of CEA and this tumour
marker is more sensitive in detecting CLM and lymph node
metastases than a local recurrence or lung metastases [1–3].
CEA levels are also frequently elevated in other forms of
cancers as well as several benign conditions such as inflam-
matory bowel disease, pancreatitis and benign liver disease
and among smokers [4, 5]. Other circulating tumour markers
have been presented, but none has yet fulfilled the criteria of
high sensitivity and specificity, combined with a stable and
reproducible method of analysis and measurements from an
easily accessible compartment, such as blood or urine.
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Type IV collagen is the most abundant basement mem-
brane (BM) protein in the human body. Previous studies have
shown that type IV collagen in plasma is elevated in patients
with inoperable CLM and that the levels reflect the tumour
burden in the liver [6]. On the contrary, patients with primary
CRC (TNM stage I–III) have normal circulating levels of this
protein, which indicates that the observed increase in circulat-
ing type IV collagen is related to the CLM process. This is
further underlined by the finding of highly increased type IV
collagen expression in the stroma of CLM tissue [6]. In addi-
tion, type IV collagen expression in the vicinity of the cancer
cells in primary CRC was also found to be a risk factor for
development of a subsequent CLM [7].
Different types of CLM can be classified based on the
growth pattern of the metastases in the liver, namely the
desmoplastic, pushing and replacement types of CLM [8].
The desmoplastic type of CLM has a fibrotic capsule rich in
type IV collagen and inflammatory cells, whereas the pushing
type of CLM is devoid of a desmoplastic reaction and inflam-
matory infiltrates and only has low expression of type IV
collagen in the tumour-liver interface. The pushing type of
CLM is associated with a poor long-term survival, in contrast
to the desmoplastic type of CLM [7–11]. The replacement
type of CLM is characterized by tumour cells growing within
preserved sinusoids of the liver, with minor inflammation,
angiogenesis and no desmoplastic reaction.
The first aim of this study was to determine the circulating
type IV collagen levels in patients with surgically treated
CLM and to analyse whether this marker can be used as a
method to detect disease relapse. Secondly, we wanted to
study whether circulating levels of type IV collagen are related
to other clinical and prognostic parameters and to the type of
CLM, as there are significant differences in the expression of
this protein between the different CLM growth patterns [7].
The third aim was to investigate if type IV collagen is superior
to CEA in detecting CLM. The fourth aim was to analyse
whether a combination of both circulating markers would in-
crease the sensitivity for detecting CLM. The final aim was to
investigate if the levels of these two markers correlated to
survival.
Methods
In the present study, the analysis was performed with the am-
bition to adhere to the REMARK guidelines. The project in
relation to these guidelines is shown in Supplementary
Table 1.
Patient cohort and sample collection
Ninety-four preoperative plasma samples from a cohort of 85
consecutive individual patients who underwent surgery for
CLM at Umeå University Hospital between January 2009
and January 2012 were used (main cohort) (Fig. 1a). Seven
patients in the cohort underwent repeated liver resections due
to CLM relapse (three patients had two liver resections
preformed, and one patient had three liver resections). The
plasma sample was collected within 2 weeks prior to liver
surgery. The postoperative follow-up was done according to
standard protocols with clinical and radiological follow-up
Fig. 1 a Flowchart of patients included and excluded in the analysis of
circulating type IV collagen in patients with colorectal liver metastases
(CLM). b Flowchart of patients included and excluded in the analysis of
growth pattern of CLM
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every 3–6 months for 2 years and then every 6–12 months up
to 5 years.
For 27 (29 %) patients, a postoperative plasma sample was
collected during March 2012 (referred to as subcohort I).
These postoperative samples were collected between 6 and
42 months after liver surgery. At that time, it was not known
whether these patients had a recurrence or not; this informa-
tion was collected separately after the sample was retrieved.
As controls, plasma samples from a group of 118 healthy,
non-smoking individuals were used. These individuals donat-
ed blood samples during population-based voluntary health
controls between 1990 and 2007, and the samples were stored
in the prospective biobank of Västerbotten County Council
and Umeå University. All plasma samples were frozen and
stored at −80 °C until analysis. Clinical data were collected
from patient charts (age, gender, TNM stage of primary CRC,
preoperative CEA levels at the time of CLM surgery, onco-
logical treatment, time interval between CRC and CLM, size
of the largest CLM and number of CLM).
Assays for measurement of circulating type IV collagen
and CEA
Circulating levels of type IV collagen in serumwere measured
using the serum Collagen IV ELISA kit (Argutus Medical,
Dublin, Ireland). The samples were analysed in duplicates
according to the manufacturers’ protocol. This kit is based
on a sandwich ELISA using two monoclonal antibodies
(clones 4H12 and ID3) directed against the 7S and collage-
nous domain of type IV collagen [12].
Circulating CEA levels in the control group were measured
by a Luminex-based method using a commercially available
human circulating cancer biomarker magnetic bead panel
(Merck Millipore, Billerica, MA, USA). The samples were
analysed in duplicates according to the manufacturers’
protocol.
Tissue staining and classification of CLM type
Paraffinated sections of the largest CLM from each patient
were selected, with the largest interface between tumour-
liver parenchyma present. Both haematoxylin and eosin stain
and a chemical reticular stain were used according to earlier
descriptions [8–13, 7].
Two researchers (HN and MB) independently evaluated
the samples. The types of metastasis were classified into
desmoplastic, pushing or replacement types of CLM accord-
ing to previous descriptions [6, 7]. The desmoplastic type of
CLM is characterized by the presence of a thick desmoplastic
rim, rich in inflammatory cells, separating the CLM from the
normal liver. The pushing type of CLM grows with the tu-
mour cells pushing the liver parenchyma away with only little
desmoplasia and inflammation present at the tumour border.
The replacement type of CLM is characterized by tumour cells
growing within the normal architecture of the liver, with pre-
served sinusoids and no desmoplastic reaction or substantial
inflammation present. If multiple growth patterns were pres-
ent, the CLM type was classified as mixed. The growth pat-
terns were classified in both the main cohort (n=94) and also
analysed separately in a group of patients (n=28) (referred to
as subcohort II, Table 1, Fig. 1b). The patients in subcohort II
did not receive any kind of chemotherapy for at least 3 months
prior liver resection and could thus be used to indicate whether
chemotherapy influenced the CLM growth patterns.
Statistical analysis
SPSS version 19 and STATAversion 11 software were used for
statistical analysis. Mann-Whitney U test was used to estimate
differences between the groups, since data was not normally
distributed. The inter-rater agreement regarding the classifica-
tion of CLM growth pattern was calculated by using Cohen’s
kappa coefficient. The probability of CLM was calculated
using a logistic regression model, and the estimated probabili-
ties were used in a receiver operating characteristic (ROC)
analysis to calculate the area under the curve (AUC) for differ-
ent models. In the ROC analysis for the tumour markers, every
operation was included as an event, and subsequently, the sam-
ples for the seven patients that underwent repeated liver resec-
tion were here treated as independent observations (n=94).
When estimating the prognostic value of the tumour
markers in relation to survival, or the metastatic pattern of
CLM in relation to survival, the start for the observation was
set to the time of the first surgical intervention, whether pa-
tients underwent one or more than one liver resection. Thus,
for the seven patients that underwent repeated liver resections,
only the first preoperative sample collected at the first resec-
tion was used and the patients with missing CEAvalues (n=6)
were excluded (total events included n=79).When calculating
any relation between mortality and levels of circulating type
IV collagen and/or CEA, patients were grouped as follows:
type IV collagen and CEA both below median, one tumour
marker above the median or both markers above the median.
Differences in survival probability between groups were test-
ed using the log-rank test. The level of significance was set to
5 % for all tests.
Results
Characterization of the cohort
Patient characteristics and oncological treatment are presented
in Table 1 and the flowchart of the cohort with included and
excluded patients in Fig. 1.
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There was no gender difference between the main cohort and
subcohort I and II (p=0.964). There was a difference in gender
distribution between controls and the main cohort (p=0.02), and
the controls were younger than the CLM patients (p=0.01).
The majority of the patients received oncological treatment
for their CLM prior liver surgery (neoadjuvant or conversion
therapy) (n=53, 56 %, Table 2). Standard regimens with in-
travenous FLOX (5-fluorouracil, leucovorin and oxaliplatin),
FLV (5-fluorouracil, leucovorin) and FLIRI (5-fluorouracil,
irinotecan) were used and in some cases also combined with
antibody-based targeted treatment (bevacizumab, cetuximab
and panitumumab). The majority of patients with rectal cancer
were given radiotherapy (n=27, 61 %). Rectal cancer with
locally advanced primary tumours were usually treated with
neoadjuvant oral capecitabine or intravenous FLOX in com-
bination with radiotherapy (n=19, 20 %). Fifteen patients
underwent liver surgery before the removal of the primary
tumour (Bliver first^). The median follow-up time was
26.4 months for the study cohort.
High preoperative circulating levels of type IV collagen
in patients with CLM
Patients with CLM (n=94) had significantly higher preopera-
tive levels of circulating type IV collagen (170.2±72.5 ng/ml)
when compared to healthy controls (n=118) (104.3±33ng/ml)
(p=0.001) (Fig. 2a). There were no significant correlations
between the circulating levels of type IV collagen in the
CLM group and gender (p=0.89), age (p=0.32), the localiza-
tion of the primary CRC (p=0.48), T stage (p=0.69), N stage
(p=0.13), CEA levels (p=0.14), size of the largest CLM (p=
0.14), number of CLM (p=0.075) and time interval fromCRC
to CLM (p=0.09). There was no relation between CEA and
age (p=0.10) or gender (p=0.35) in the CLM group.
In the control group, there was a small but significant dif-
ference in the circulating type IV collagen levels related to age
(p=0.001), but not correlation between CEA and age (p=0.46).
Neither CEA nor type IV collagen levels were related to gender
in the control group (p=0.76 and p=0.98, respectively). Levels
Table 1 Patient characteristics







Gender (M/F) 63/31 18/9 18/10 58/60
Age (mean±SD) 65.3±8.6 66.2±7.5 69.9±8.3 54.6±10.3
CRC location (colon/rectum) 50/44 15/12 15/13 –
T stage CRC
1 3 1 3 –
2 7 1 4
3 44 12 15
4 20 5 2
Unknown 20 8 4
N stage CRC
N0 23 8 10 –
N1 23 5 10
N2 33 8 7
Unknown 15 6 1
Type IV collagen (ng/ml; mean±SD) 170.1±72.5 – 155.4±80.6 104.4±33.0
Recurrent CLM – 214.0±145.4 – –
Disease-free – 82.4±13.7 – –
CEA (ng/ml; median, range) 7.6 (0.8–2073) 7.7 (1.2–200) 11.7 (0.8–96) 1.3 (0.2–4.2)
Time interval CRC-CLM in months (median, range) 0 (0–30) 0 (0–30) 10 (0–30) –
Synchronous/metachronous CLMa 62/32 20/7 9/19 –
Type of CLM
Pushing 36 8 15 –
Desmoplastic 20 12 8
Replacement 2 0 1
Mixed 9 2 4
Not classifiable 16 2 0
Unknown 11 3 –
a Synchronous CLM here defined as CLM diagnosed within 6 months from diagnosis of primary tumour
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of the two tumour markers in relation to age and gender for
both groups are shown in Supplementary Table 2a, b.
High levels of collagen IV in patients with recurrent CLM
The 27 patients with a long-term follow-up postoperative sample
(subcohort I) were divided into a group with recurrent disease
(n=17) and patients with no evidence of recurrent disease (n=
10). Patient characteristics are found in Table 1. All measured
values of type IV collagen, recurrent disease and the site of
recurrence for subcohort II are shown in Supplementary
Table 3. Patients with recurrent disease (n=17), including all
types of recurrences, had significantly higher levels of type IV
collagen (200.1±136.9 ng/ml), compared to the patients with no
recurrent disease (n=10) (82.3±13.7 ng/ml) (p=0.001) (Fig. 2b).
Fourteen (83 %) of the patients with recurrent disease had
CLM and presented with high collagen levels (214±
145 ng/ml) compared to the group with no recurrent disease
(82.3±13.7 ng/ml) (p=0.001). The three patients (18 %) with
a non-liver recurrence had a local rectal recurrence with a
lymph node metastasis, unclassified ovarian mass or lung me-
tastasis only (Fig. 2b).
Preoperative circulating type IV collagen versus CEA
levels in patients with CLM
The ROC analysis revealed that type IV collagen is not supe-
rior to CEA alone in detecting CLM (Fig. 3a). When combin-
ing both markers as independent variables in a logistic regres-
sion, the AUC was significantly increased when compared to
either CEA or type IV collagen alone (p=0.001 and p<0.001,
respectively) (Fig. 3a, Table 3). Values of sensitivity, specificity
Table 2 Oncological treatment
CLM (n=94) Subcohort I (n=27)
















Fig. 2 a Circulating type IV collagen in healthy controls compared to
preoperative samples from patients with CLM. Patients with CLM had
significantly higher levels of circulating type IV collagen (170.2±
72.5 ng/ml) compared to controls (104.3±33 ng/ml) (***p=0.001). b
Circulating levels of type IV collagen in patients with a postoperative
follow-up sample 6–42 months after liver surgery for CLM. Patients with
no recurrence (n=10), recurrence of CLM (n=14) or with a non-liver
recurrence (n=3). Patients with recurrent CLM had significantly higher
type IV collagen levels (214±145 ng/ml) compared to the patients with
no recurrence (82.3±13.7 ng/ml) (***p=0.001). The circles represent the
outliers/ samples that are outliers outside of the whiskers
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and accuracy for type IV collagen and CEA are presented in
Table 4. The calculated optimal cutoff for type IV collagen
and CEA in the ROC was 115 and 2.8 ng/ml, respectively.
This cutoff for CEA differs from the clinical cutoff of 5 ng/ml.
The type IV collagen levels in the preoperative samples of
patients with CLM (n=94) were more frequently elevated (n=
76, 80.9 %) than the CEA level (n=53, 56.4 %) (Fig. 3b),
when using a calculated optimal cutoff value of 115 ng/ml
for type IV collagen and the clinically recommended cutoff
of 5 ng/ml for CEA. Of the patients, 93.6 % (n=88) presented
with at least one marker above these cutoff levels of 115 ng/ml
for collagen IVand the clinical cutoff of 5 ng/ml (Fig. 3b). For
CEA, six (6.4 %) patient samples were missing. These six
patients all had collagen IV levels above the cutoff.
Low levels of type IV collagen and CEA are related to high
survival
To study the prognostic value of a combination of tumour
markers, a survival analysis based on both the IV collagen
levels and CEAwas performed. In this analysis, patients were
grouped based on bothmarkers being below the median value,
one marker above median or both markers above the median
(Fig. 4a). The correlation between the levels of circulating
type IV collagen and CEA in relation to mortality revealed
that patients with low levels of both markers (n=18) had the
best survival (92 %), patients with one marker above median
(n=44) displayed a survival of 70 % and patients with both
markers elevated (n=17) had the poorest survival of 47 %
three years after surgery (Fig. 4a).
Circulating type IV collagen levels are not related
to metastatic pattern of CLM
Two independent observers classified the metastatic growth pat-
tern of the CLM, with an inter-rater agreement of 0.86. The
different metastatic growth patterns are illustrated in
Supplementary Fig. 1. For 27 patients, no tissue sample was
available for analysis due to substantial tumour regression caused
by chemotherapy and no viable cancer cells left (n=16), the use
of radiofrequency ablation (RFA) (n=4), aborted surgery due to
disseminated disease (n=3) ormissing samples (n=4). TheCLM
growth pattern was thus classified in 67 patients (Fig. 1b).
The dominant pattern in each CLM was used for classifica-
tion, and for themajority of cases (n=58, 87%), only one pattern
was present. In some cases, the CLM were classified as mixed
due to features of pushing, desmoplastic and replacement growth
pattern (n=9, 13 %). Several of the 67 patients included in the
histological analysis had received some form of chemotherapy
prior to liver surgery (n=39, 58 %, Table 2). However, the met-
astatic pattern was still easy to define for most of these patients.
There was no relationship between the major types of CLM
(desmoplastic and pushing) and the circulating collagen IV
levels. The replacement type of CLM presented with normal
type IV collagen levels, but this group was too small to allow
for statistical analysis.
To eliminate the possible effects of preoperative oncologi-
cal treatment on CLM growth pattern, patients that had not
received any kind of chemotherapy at least 3 months prior to
liver surgery (n=28) were analysed separately (subcohort II).
Patient characteristics of subcohort II are shown in Table 1.
There was no significant difference in type IV collagen levels
between the pushing and the desmoplastic group in subcohort
II. The number of patients within the replacement and the
mixed group were too small to allow for statistical compari-
son. Thus, there were no significant differences in the type IV
collagen levels between desmoplastic and pushing type of
CLM, regardless of whether they had received chemotherapy
prior to surgery or not (p=0.632 and p=0.144, respectively).
The pushing type of CLM is related to poor survival
A Kaplan-Meier analysis of the patients with pushing (n=
36) and desmoplastic (n=20) type of CLM revealed that
Fig. 3 a ROC curve analysis of type IV collagen, CEA and a
combination of both markers. Based on logistic regression, the area
under the curve (AUC) was compared and the combination of markers
is significantly better then CEA or type IV collagen alone (p=0.001 and
p<0.001, respectively). b Comparison of percentage of CLM patients
with elevated preoperative levels of type IV collagen (COL IV) and
CEA and percentage of patients with at least one marker elevated. Type
IV collagen levels were increased above cutoff (115 ng/ml) in 81 % of
patients with CLM compared to only 56 % of patients presenting with
elevated levels of CEA (cutoff 5 ng/ml). Ninety-three percent of the
patients presented with at least one of the markers above these levels
Table 3 Area under the curve (AUC) for collagen IV, CEA and the
combination of collagen IV + CEA
Marker AUC Standard error p value
Collagen IV 0.806 0.31 –
CEA 0.926 0.19 –
Collagen IV+CEA 0.955 0.14 0.001 and <0.001*
*p values for comparison of AUC-combined marker versus AUC for
CEA and collagen IV, respectively
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patients with the pushing type had a poorer survival com-
pared to the desmoplastic type of CLM (Fig. 4b). Sixteen
patients (44 %) in the pushing group had died compared
to two patients (10 %) in the desmoplastic group (p=
0.011). Due to few cases of the other metastatic patterns
(replacement n=2; mixed n=9), they could not be statisti-
cally analysed.
Discussion
Circulating type IV collagen has been shown to be a potential
tumour marker for non-resectable CLM, and the levels of this
marker reflect the tumour burden in the liver [6]. Interestingly,
patients with primary CRC do not have increased type IV
collagen levels, which indicate that the increased type IV col-
lagen levels are related to the liver metastatic process itself. In
this study, it is shown that the preoperative circulating type IV
collagen levels in patients with resectable CLM are signifi-
cantly elevated when compared to healthy controls. In addi-
tion, patients with recurrent CLM again have increased levels
of type IV collagen, whereas patients without recurrence do
not.
It is not known why patients with CLM have increased
levels of circulating type IV collagen, but earlier studies have
shown that CLM are rich in type IV collagen within the me-
tastasis [7, 6]. The elevated levels might be caused by an
increased production and/or increased degradation. The in-
creased production seen in CLM may be caused by an in-
creased production by the cancer cells themselves and/or by
the myofibroblasts in the liver producing the tumour stroma.
In primary CRC that developed CLM, a strong expression of
type IV collagen in the vicinity of the cancer cells was seen;
this was not observed in primary CRC that never metastasized
[7]. A study by Burnier et al. showed that cancer cells with
type IV collagen production are highly liver-metastatic and
that this trait is lost when their production of this collagen is
blocked [14]. This indicates that an upregulation of type IV
collagen production in tumour cells might be of importance
for the liver-metastatic properties of CRC cells.
In this study, circulating type IV collagen levels were com-
pared to the conventional tumour marker CEA. Type IV col-
lagen was not better than CEA in the ROC analysis when
studying either marker alone. However, in this analysis the
clinically recommended cutoff level 5 ng/ml is not taken into
consideration when calculating the curve. Instead, the cutoff
level for CEA by using a ROC curve analysis on the present
cohort was estimated to be at 2.8 ng/ml. Thus, there is a dis-
crepancy between the clinically recommended cutoff value for
CEA and the cutoff value that results from the ROC curve
analysis. This is further underlined by the present data show-
ing that when the clinically recommended cutoff level for
CEA (5 ng/ml) was used, circulating type IV collagen was
clearly more sensitive in detecting CLM than CEA. Thus, type
Table 4 Specificity, sensitivity,
cutoff and accuracy for the
calculated values based on the
cohort for type IV collagen (COL
IV) and the responding values
when using the clinically






CEA calculated 9.3 80.7 2.8 0.86
CEA clinical 0.0 56.4 5.0 0.77
COL IV calculated 34.7 80.9 115 0.72
Fig. 4 a Survival analysis of patients at a median follow-up time of
26.4 months. Grouped as CEA and type IV collagen both below median
value (none), one tumour marker above median (1) and both markers
above median (2). Patients with both markers above median display the
poorest survival. b Analysis of survival of patients with the pushing
versus the desmoplastic growth pattern. Patients with a pushing type of
CLM have significantly poorer survival when compared to the
desmoplastic type (p=0.011)
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IV collagen levels were elevated in 81 % of patients with
CLM, compared to CEA being elevated in 56 % of patients.
When using the calculated CEAvalue based on this cohort,
sensitivity, specificity and accuracy were better than for type
IV collagen. But when using the clinical cutoff at 5 ng/ml, the
specificity of CEA was still better than for type IV collagen,
but the sensitivity was decreased to 56.4 compared to 80.9 for
type IV collagen. Accuracy for both markers was similar.
Positive predictive value and negative predictive value are
not applicable on this constructed cohort, since these values
are dependent on the prevalence of the disease studied.
The combination of both markers resulted in a significantly
increased AUC, which indicates that the combination of CEA
and type IV collagen improves the sensitivity in detecting
CLM when compared to CEA alone (p = 0.001) .
Additionally, patients with both CEA and type IV collagen
elevated above the median had a significantly poorer survival
(47 %), compared to patients with only one (70 %) or no
marker elevated (92 %) 3 years after surgery, implying a prog-
nostic significance using the combination of tumour markers
in CLM patients.
Our study has some limitations. First, the controls were
younger than the CLM group studied. A gender- and age-
matched control group would have been more optimal. A
small but significant correlation between age and circulating
type IV collagen was observed within the control group.
Earlier studies have shown that type IV collagen levels are
not related to age [15]; however, the findings in the present
study indicate that such a difference might exist but might also
be caused by a too small control group with few older indi-
viduals. In the CLM group, there was no correlation between
age and collagen IV. CEA levels have been reported to relate
to age [16], but here, no such correlation was observed for the
control group or the CLM group. Another limitation of this
study is that follow-up samples were not available from the
entire cohort. However, the postoperative samples that were
available had quite similar proportions of patients with a re-
current CLM and those without a recurrence. Nevertheless,
the present data should be verified in a larger cohort with
long-term samples.
In the present study, the correlation of any one of the CLM
growth patterns to high circulating levels of type IV collagen
was analysed, as there are significant differences in type IV
collagen expression among these. However, no such correla-
tion was found. Therefore, preoperative circulating type IV
collagen levels are not related to the CLM growth patterns.
It was also verified in this study that the pushing type of CLM
is associated to poor prognosis as previously described [7–9]
with amortality of 44%, compared to a mortality of only 10%
in the desmoplastic group.
CLM patients are often diagnosed with their primary CRC
prior diagnosis of CLM, and about 50 % of CRC patients will
develop CLM. As metastatic disease ultimately is what kills
the patients, it is essential to detect resectable metastatic dis-
ease early, thus enabling curative metastatic surgery that pro-
vides the only hope of lasting cure. There is a great need for
better tumour markers allowing for early detection of CLM, as
CEA is only elevated in about half of CRC patients. Still only
about 22 % of patients with CLM are eligible for resection,
and increasing this percentage would provide patients with a
chance to actually survive their disease. Type IV collagen in
this study has a higher sensitivity for detecting CLM than
CEA, and the combination of both markers as shown in this
study is significantly better in detecting CLM than using CEA
alone (p=0.001). These markers represent different tumour
compartments, and measuring substances related to both the
cancer cell (CEA) and the stroma (type IV collagen) could
provide a better chance to detect CLM than using one marker
only.
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